CMS Considers Broadened PET Scan Coverage For Staging Of Cervical Cancer
This article was originally published in The Gray Sheet
Executive Summary
Under a national coverage analysis opened May 8, CMS says it will evaluate whether to cover positron emission tomography more broadly for the staging of cervical cancer outside of clinical studies
You may also be interested in...
Reimbursement In Brief
CMS updates coverage policy on PET for cervical cancer: The Medicare agency finds there is now enough evidence to call positron emission tomography for cervical cancer "reasonable and necessary" for staging cervical cancer patients, and will no longer require data collection as a condition of coverage (1"The Gray Sheet" May 18, 2009). CMS will cover one PET scan for staging beneficiaries with biopsy-proven cervical cancer to help determine the location or extent of the tumor. Coverage is limited to the following therapeutic uses: to determine if the patient is a good candidate for an invasive diagnostic or therapeutic procedure; to determine the best anatomic location for an invasive procedure; or to determine the anatomic extent of a tumor when treatment depends on the extent of the tumor. The imaging test remains non-covered as a tool to diagnose cervical cancer. This recent decision does not restrict the use of PET scans already covered for detection of metastases during the pre-treatment management phase of patients with newly diagnosed and locally advanced cervical cancer who show no extra-pelvic metastasis on conventional imaging tests such as CT or MRI (2"The Gray Sheet" April 13, 2009)
Reimbursement In Brief
CMS updates coverage policy on PET for cervical cancer: The Medicare agency finds there is now enough evidence to call positron emission tomography for cervical cancer "reasonable and necessary" for staging cervical cancer patients, and will no longer require data collection as a condition of coverage (1"The Gray Sheet" May 18, 2009). CMS will cover one PET scan for staging beneficiaries with biopsy-proven cervical cancer to help determine the location or extent of the tumor. Coverage is limited to the following therapeutic uses: to determine if the patient is a good candidate for an invasive diagnostic or therapeutic procedure; to determine the best anatomic location for an invasive procedure; or to determine the anatomic extent of a tumor when treatment depends on the extent of the tumor. The imaging test remains non-covered as a tool to diagnose cervical cancer. This recent decision does not restrict the use of PET scans already covered for detection of metastases during the pre-treatment management phase of patients with newly diagnosed and locally advanced cervical cancer who show no extra-pelvic metastasis on conventional imaging tests such as CT or MRI (2"The Gray Sheet" April 13, 2009)
CMS proposes to cover PET scans for staging cervical cancer
Under Aug. 13 proposed decision, the Medicare agency would lift data collection requirements for positron emission tomography scans of cervical cancer patients when used to make "meaningful changes in therapeutic management." The proposal limits coverage to one PET scan with the radioactive tracer F-18 fluorodeoxyglucose when needed to locate a tumor or determine the extent of the tumor in specific therapeutic situations. CMS also proposes non-coverage of PET in diagnosing cervical cancer (1"The Gray Sheet" June 15, 2009). The agency opened the coverage analysis May 8 at the request of two oncology professors (2"The Gray Sheet" May 18, 2009). Comments are due Sept. 12, and the agency plans a final ruling by Nov. 11